Newsletter

128940 - Hanmi Pharm. Co., Ltd.

128940 Summary

Biopharma

Stock Price & Overview

₩471,000 -4,500 (-0.95%) Close · Sep 8, 2026 KST

KOSPI | ₩KRW | Close: ₩471,000 ≈ US$336 · Market cap ₩6.0tn (≈ $4.3bn)

Home › 128940 › Filings

5% Ownership Report — Large Holdings

DART

Hanmi Pharm. Co., Ltd.

Filed Sep 8, 2026 KST · Ownership · receipt 20260908000370

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.

Korean form name: 주식등의대량보유상황보고서(일반)

128940

Price: ₩471,000
Change: -0.95%
Market cap: ₩6.0tn
Prev. close: ₩475,500

128940 Summary Compare to Peers

128940 data on kstock

Financials: 11 fiscal years
Valuation: Daily P/E, P/S, P/B, P/CF
Earnings: Eight quarters
Dividends: Per-share history

Every figure is taken from Hanmi Pharm. Co., Ltd.'s own DART filings and matched on IFRS account codes, so a line holds across years where the Korean wording changed.

kstock analysis on 128940

Hanmi Pharmaceutical: The 28% Margin Arrived In One Wire Transfer

Aug 31, 1:13 AM

All 128940 analysis

More 128940 filings

128940 - Hanmi Pharm. Co., Ltd.

5% Ownership Report — Large Holdings

128940

128940 data on kstock

kstock analysis on 128940

Hanmi Pharmaceutical: The 28% Margin Arrived In One Wire Transfer

More 128940 filings

Investor Relations Event

Change in the Largest Shareholder's Holdings

Change in the Largest Shareholder's Holdings

Material matter affecting investment judgment

Material matter affecting investment judgment

Material matter affecting investment judgment ×2